Amdocs Enterprise Value vs Free Cash Flow Analysis

DOX Stock

USD 86.13 1.02 1.20%

Amdocs financial indicator trend analysis is way more than just evaluating Amdocs prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Amdocs is a good investment. Please check the relationship between Amdocs Enterprise Value and its Free Cash Flow accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amdocs. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Amdocs Stock please use our How to Invest in Amdocs guide.

Enterprise Value vs Free Cash Flow

Enterprise Value vs Free Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Amdocs Enterprise Value account and Free Cash Flow. At this time, the significance of the direction appears to have very week relationship.

The correlation between Amdocs' Enterprise Value and Free Cash Flow is 0.28. Overlapping area represents the amount of variation of Enterprise Value that can explain the historical movement of Free Cash Flow in the same time period over historical financial statements of Amdocs, assuming nothing else is changed. The correlation between historical values of Amdocs' Enterprise Value and Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Enterprise Value of Amdocs are associated (or correlated) with its Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow has no effect on the direction of Enterprise Value i.e., Amdocs' Enterprise Value and Free Cash Flow go up and down completely randomly.

Correlation Coefficient

0.28

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Enterprise Value

Enterprise Value (or EV) is usually referred to as Amdocs theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Amdocs debt, but would also pocket its cash. Enterprise Value is more accurate representation of Amdocs value than its market capitalization because it takes into account all of Amdocs existing debt. A measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents.

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Most indicators from Amdocs' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Amdocs current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amdocs. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Amdocs Stock please use our How to Invest in Amdocs guide.At this time, Amdocs' Sales General And Administrative To Revenue is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to rise to 14.45 in 2024, whereas Selling General Administrative is likely to drop slightly above 390.6 M in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	1.6B	1.7B	2.0B	1.1B
Total Revenue	4.6B	4.9B	5.6B	3.1B

Gross Profit Total Revenue

Amdocs fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock Total Equity	Property Plant And Equipment Gross	Common Stock	Current Deferred Revenue	Other Liab
Total Assets		0.56	0.51	0.95	0.96	0.65	0.2	0.77	0.15	0.43	0.97	0.75	0.44	0.93	-0.88	0.65	0.73	-0.61	0.94	0.81	0.04	0.95	0.64	0.94	0.53	0.95
Short Long Term Debt Total	0.56		0.5	0.44	0.49	0.73	0.53	0.76	-0.05	-0.22	0.68	0.67	-0.25	0.67	-0.76	0.61	0.85	-0.77	0.57	0.15	-0.14	0.62	0.73	0.63	0.09	0.47
Other Current Liab	0.51	0.5		0.37	0.32	0.85	0.79	0.78	-0.31	-0.05	0.59	0.77	0.03	0.37	-0.71	0.86	0.71	-0.83	0.67	0.19	-0.23	0.51	0.85	0.56	0.56	0.51
Total Current Liabilities	0.95	0.44	0.37		0.97	0.48	-0.01	0.69	0.32	0.48	0.88	0.65	0.52	0.92	-0.77	0.47	0.65	-0.46	0.82	0.86	0.11	0.94	0.47	0.92	0.47	0.87
Total Stockholder Equity	0.96	0.49	0.32	0.97		0.46	-0.06	0.67	0.35	0.54	0.87	0.65	0.55	0.93	-0.75	0.45	0.66	-0.41	0.8	0.89	0.1	0.92	0.45	0.9	0.38	0.86
Property Plant And Equipment Net	0.65	0.73	0.85	0.48	0.46		0.82	0.93	-0.35	-0.02	0.74	0.9	0.0	0.55	-0.86	0.98	0.87	-0.95	0.79	0.28	-0.11	0.66	1.0	0.7	0.57	0.67
Net Debt	0.2	0.53	0.79	-0.01	-0.06	0.82		0.6	-0.62	-0.47	0.39	0.57	-0.45	0.13	-0.58	0.79	0.53	-0.84	0.48	-0.28	-0.23	0.2	0.82	0.26	0.41	0.3
Retained Earnings	0.77	0.76	0.78	0.69	0.67	0.93	0.6		-0.13	0.1	0.81	0.95	0.16	0.72	-0.9	0.89	0.95	-0.9	0.81	0.49	-0.07	0.82	0.93	0.85	0.54	0.75
Accounts Payable	0.15	-0.05	-0.31	0.32	0.35	-0.35	-0.62	-0.13		0.5	0.0	-0.15	0.47	0.19	0.16	-0.34	-0.01	0.41	-0.08	0.44	-0.21	0.17	-0.35	0.11	-0.35	-0.06
Cash	0.43	-0.22	-0.05	0.48	0.54	-0.02	-0.47	0.1	0.5		0.2	0.17	0.96	0.21	-0.03	0.1	0.06	0.24	0.27	0.84	0.16	0.33	-0.03	0.3	0.21	0.31
Non Current Assets Total	0.97	0.68	0.59	0.88	0.87	0.74	0.39	0.81	0.0	0.2		0.76	0.2	0.93	-0.96	0.71	0.77	-0.74	0.97	0.63	0.02	0.93	0.73	0.93	0.51	0.94
Non Currrent Assets Other	0.75	0.67	0.77	0.65	0.65	0.9	0.57	0.95	-0.15	0.17	0.76		0.25	0.66	-0.83	0.9	0.91	-0.82	0.79	0.52	-0.16	0.78	0.9	0.81	0.56	0.77
Cash And Short Term Investments	0.44	-0.25	0.03	0.52	0.55	0.0	-0.45	0.16	0.47	0.96	0.2	0.25		0.22	-0.05	0.13	0.1	0.19	0.29	0.87	0.0	0.37	-0.01	0.34	0.34	0.37
Net Receivables	0.93	0.67	0.37	0.92	0.93	0.55	0.13	0.72	0.19	0.21	0.93	0.66	0.22		-0.87	0.49	0.74	-0.58	0.83	0.67	0.11	0.93	0.54	0.92	0.34	0.86
Common Stock Shares Outstanding	-0.88	-0.76	-0.71	-0.77	-0.75	-0.86	-0.58	-0.9	0.16	-0.03	-0.96	-0.83	-0.05	-0.87		-0.81	-0.84	0.89	-0.94	-0.48	0.03	-0.89	-0.85	-0.91	-0.53	-0.88
Non Current Liabilities Total	0.65	0.61	0.86	0.47	0.45	0.98	0.79	0.89	-0.34	0.1	0.71	0.9	0.13	0.49	-0.81		0.8	-0.89	0.81	0.34	-0.17	0.63	0.98	0.67	0.64	0.69
Other Current Assets	0.73	0.85	0.71	0.65	0.66	0.87	0.53	0.95	-0.01	0.06	0.77	0.91	0.1	0.74	-0.84	0.8		-0.83	0.72	0.44	-0.08	0.78	0.86	0.8	0.4	0.65
Other Stockholder Equity	-0.61	-0.77	-0.83	-0.46	-0.41	-0.95	-0.84	-0.9	0.41	0.24	-0.74	-0.82	0.19	-0.58	0.89	-0.89	-0.83		-0.76	-0.14	0.13	-0.62	-0.95	-0.67	-0.53	-0.64
Total Liab	0.94	0.57	0.67	0.82	0.8	0.79	0.48	0.81	-0.08	0.27	0.97	0.79	0.29	0.83	-0.94	0.81	0.72	-0.76		0.64	-0.05	0.88	0.79	0.89	0.64	0.95
Total Current Assets	0.81	0.15	0.19	0.86	0.89	0.28	-0.28	0.49	0.44	0.84	0.63	0.52	0.87	0.67	-0.48	0.34	0.44	-0.14	0.64		0.07	0.75	0.26	0.72	0.43	0.72
Short Term Debt	0.04	-0.14	-0.23	0.11	0.1	-0.11	-0.23	-0.07	-0.21	0.16	0.02	-0.16	0.0	0.11	0.03	-0.17	-0.08	0.13	-0.05	0.07		0.03	-0.11	0.01	-0.07	-0.01
Common Stock Total Equity	0.95	0.62	0.51	0.94	0.92	0.66	0.2	0.82	0.17	0.33	0.93	0.78	0.37	0.93	-0.89	0.63	0.78	-0.62	0.88	0.75	0.03		0.65	1.0	0.44	0.89
Property Plant And Equipment Gross	0.64	0.73	0.85	0.47	0.45	1.0	0.82	0.93	-0.35	-0.03	0.73	0.9	-0.01	0.54	-0.85	0.98	0.86	-0.95	0.79	0.26	-0.11	0.65		0.69	0.57	0.67
Common Stock	0.94	0.63	0.56	0.92	0.9	0.7	0.26	0.85	0.11	0.3	0.93	0.81	0.34	0.92	-0.91	0.67	0.8	-0.67	0.89	0.72	0.01	1.0	0.69		0.47	0.91
Current Deferred Revenue	0.53	0.09	0.56	0.47	0.38	0.57	0.41	0.54	-0.35	0.21	0.51	0.56	0.34	0.34	-0.53	0.64	0.4	-0.53	0.64	0.43	-0.07	0.44	0.57	0.47		0.63
Other Liab	0.95	0.47	0.51	0.87	0.86	0.67	0.3	0.75	-0.06	0.31	0.94	0.77	0.37	0.86	-0.88	0.69	0.65	-0.64	0.95	0.72	-0.01	0.89	0.67	0.91	0.63

Click cells to compare fundamentals

Amdocs Account Relationship Matchups

Amdocs fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	6.3B	6.5B	6.4B	6.4B	7.4B	4.5B
Other Current Liab	794.4M	886.6M	821.3M	849.4M	976.9M	1.0B
Total Current Liabilities	1.2B	1.3B	1.3B	1.4B	1.6B	1.0B
Total Stockholder Equity	3.6B	3.6B	3.5B	3.5B	4.1B	2.8B
Property Plant And Equipment Net	903.4M	931.9M	971.2M	951.9M	1.1B	1.1B
Net Debt	50.0M	172.1M	253.5M	287.2M	258.5M	271.4M
Retained Earnings	5.3B	5.9B	6.2B	6.5B	7.5B	7.9B
Accounts Payable	930.3M	121.2M	134.4M	293.3M	337.3M	428.4M
Cash	983.2M	709.1M	573.4M	520.1M	598.1M	720.1M
Non Current Assets Total	4.3B	4.4B	4.4B	4.5B	5.2B	2.6B
Non Currrent Assets Other	488.6M	630.7M	574.9M	631.6M	726.3M	762.6M
Cash And Short Term Investments	983.9M	965.6M	818.0M	742.5M	853.9M	1.0B
Net Receivables	861.0M	866.8M	946.8M	944.5M	1.1B	618.6M
Common Stock Shares Outstanding	133.2M	128.0M	121.9M	118.5M	106.6M	144.3M
Liabilities And Stockholders Equity	6.3B	6.5B	6.4B	6.4B	7.4B	4.5B
Non Current Liabilities Total	1.5B	1.6B	1.6B	1.5B	1.7B	1.8B
Other Current Assets	229.6M	235.1M	238.4M	224.6M	258.3M	307.0M
Other Stockholder Equity	(1.7B)	(2.3B)	(2.6B)	(3.0B)	(2.7B)	(2.5B)
Total Liab	2.7B	2.9B	2.8B	2.9B	3.3B	1.7B
Total Current Assets	2.1B	2.1B	2.0B	1.9B	2.2B	1.9B
Short Term Debt	159.1M	58.7M	43.3M	40.0M	46.0M	43.7M
Property Plant And Equipment Gross	903.4M	931.9M	971.2M	951.9M	1.1B	1.1B
Accumulated Other Comprehensive Income	11.7M	9.3M	(72.5M)	(53.3M)	(47.9M)	(45.5M)
Common Stock	4.5M	4.5M	4.5M	4.6M	5.3M	4.4M
Current Deferred Revenue	126.8M	237.4M	253.7M	170.6M	196.2M	184.3M
Other Liab	542.4M	586.2M	750.3M	793.9M	913.0M	469.4M
Other Assets	423.9M	488.6M	630.7M	574.9M	661.2M	386.6M
Good Will	2.6B	2.6B	2.7B	2.7B	3.2B	1.9B
Intangible Assets	296.3M	259.0M	178.3M	181.5M	163.4M	317.6M
Property Plant Equipment	354.0M	723.6M	931.9M	971.2M	1.1B	1.2B
Short Term Investments	752K	256.5M	244.6M	222.5M	200.2M	266.3M
Net Tangible Assets	660.6M	567.8M	711.0M	676.6M	609.0M	676.1M

Pair Trading with Amdocs

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amdocs position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amdocs will appreciate offsetting losses from the drop in the long position's value.

Moving against Amdocs Stock

0.74	NN	Nextnav Acquisition Corp Tech Boost	Pair Corr
0.69	EGIO	Edgio Inc Downward Rally	Pair Corr
0.59	GB	Global Blue Group Downward Rally	Pair Corr
0.55	VERI	Veritone Financial Report 7th of May 2024	Pair Corr

The ability to find closely correlated positions to Amdocs could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amdocs when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amdocs - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amdocs to buy it.

The correlation of Amdocs is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amdocs moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amdocs moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Amdocs can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Amdocs offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Amdocs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Amdocs Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Amdocs Stock:

How To Invest In Amdocs

Details

Is Amdocs Stock a good investment?

Details

What is Amdocs' Net Worth?

Details

Largest IT Consulting & Other Services Companies

View

Largest Software - Infrastructure Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amdocs. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Amdocs Stock please use our How to Invest in Amdocs guide.

You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Complementary Tools for Amdocs Stock analysis

When running Amdocs' price analysis, check to measure Amdocs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amdocs is operating at the current time. Most of Amdocs' value examination focuses on studying past and present price action to predict the probability of Amdocs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amdocs' price. Additionally, you may evaluate how the addition of Amdocs to your portfolios can decrease your overall portfolio volatility.

	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites

Is Amdocs' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amdocs. If investors know Amdocs will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amdocs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.18

Dividend Share

1.74

Earnings Share

4.68

Revenue Per Share

41.665

Quarterly Revenue Growth

0.05

The market value of Amdocs is measured differently than its book value, which is the value of Amdocs that is recorded on the company's balance sheet. Investors also form their own opinion of Amdocs' value that differs from its market value or its book value, called intrinsic value, which is Amdocs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amdocs' market value can be influenced by many factors that don't directly affect Amdocs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Amdocs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amdocs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amdocs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Amdocs Enterprise Value vs Free Cash Flow Analysis

Enterprise Value vs Free Cash Flow

Enterprise Value vs Free Cash Flow Correlation Analysis

Correlation Coefficient

Enterprise Value

Free Cash Flow

Amdocs fundamental ratios Correlations

Amdocs Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Amdocs fundamental ratios Accounts

Pair Trading with Amdocs

Moving against Amdocs Stock

Complementary Tools for Amdocs Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Common Stock	+ 1.0	Common Stock Total Equity
Non Current Liabilities Total	+ 0.98	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 0.98	Non Current Liabilities Total
Non Current Assets Total	+ 0.97	Total Assets
Total Stockholder Equity	+ 0.97	Total Current Liabilities

Common Stock Shares Outstanding	- 0.96	Non Current Assets Total
Property Plant And Equipment Gross	- 0.95	Other Stockholder Equity
Other Stockholder Equity	- 0.95	Property Plant And Equipment Net
Total Liab	- 0.94	Common Stock Shares Outstanding
Common Stock	- 0.91	Common Stock Shares Outstanding
Other Stockholder Equity	- 0.9	Retained Earnings